Global Precision Medicine Growth Opportunities, Forecast to 2025

  • ID: 4060478
  • Report
  • Region: Global
  • 154 Pages
  • Frost & Sullivan
1 of 3
Strategies and Tactics for Accelerating Growth in a Transforming Market

Precision medicine aims to integrate personalized health data both from direct (quantifiable) and indirect (quantifiable) sources probing the deepest mysteries affecting individual health and well-being. Rising pressures to decrease healthcare cost globally, emergence of value-based reimbursement models, and healthcare digitization trends are transitioning the treatment model from ‘One-size-fits-all’ to stratified and outcome-based targeted therapies called precision medicine.

In the past few decades, our scientific knowledge and technological advancements around genomics has increased exponentially, making cost and time no longer a barrier for population-level genome profiling. Integration of these genomic and lifestyle data into clinical workflow to derive deeper insight into genetic and chronic deceases is unique to the precision medicine concept. However, the precision medicine concept is a nascent one that needs further refinement at fundamental levels with incremental progress towards more effective and targeted drugs that are precisely accurate in reducing the treatment uncertainty, to ultimately revolutionize the care delivery model in the long run. Also, the current legal and ethical frameworks both at global and regional levels were built with a very different generation of medical products and practices in mind and raise some serious challenges for the revolutionary concept of precision medicine practice.

Research Scope:

The research service analyzes the key building-blocks for precision medicine ecosystem to provide strategic imperatives and growth opportunities for key industry participants. The study also captures both global and regional flavours for precision medicine market opportunity realization such as market projections, drivers and restraints, country readiness index, and major government and commercial initiatives. Finally, the study provides live case studies and innovative business models for leading select companies in the precision medicine space.

Key Questions This Study Will Answer

  • What is Precision Medicine and its impetus for the healthcare industry?
  • What does the precision medicine ecosystem look like? Who are the key stakeholders and what are their roles?
  • What are the current gaps in the precision medicine ecosystem and how can these be filled by industry partners?
  • How big is the precision medicine market? What are the growth opportunities by major therapeutic areas, market segments, and technologies?
  • What are the major market drivers and restraints for the precision medicine market and what are their use cases?
  • Which countries demonstrate the highest growth opportunities for precision medicine? How are the regulatory and reimbursement landscapes evolving across these countries?
  • What are the most promising business models emerging in the healthcare space to enable precision medicine practice?
  • What are the strengths of my business against competition? Are these strengths sustainable over the next 5-10 years?
  • What winning and losing strategies can be gleaned from the existing market case studies and companies to watch?
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Executive Summary
  • Key Questions
  • 6 Big Themes for Precision Medicine
  • Precision Medicine-Regional Market Overview
  • Heat Map-Precision Medicine Readiness Index by Selected Countries
  • Strategic Imperatives-Growth Opportunities by Key Segments
  • Precision Medicine-Patient Stratification Data Sources
2. Research Scope and Market Definition
  • Research Scope
  • What is Precision Medicine?
  • What is the Difference between Personalized vs Precision Medicine?
  • Definition-Precision Medicine
  • Precision Medicine-Key Segments and Data Sources
3. Growth Environment-Introduction and Overview
  • Global Precision Medicine Market-Macro to Micro Visioning
  • Micro Industry Challenges
  • Failing Blockbuster Medicine Model-One Size Doesn’t Fit All
  • Evolving Pharma / Biotech Business Model
  • Population Health Management, Central to VBR, is Difficult Business for Providers
  • Patients Bringing a Consumer Mindset to Healthcare Interactions
  • New Paradigm Shift in Treatment
  • What Will Precision Medicine Achieve?
  • Precision Medicine Essentials-Patient Stratification Data and Sources
  • Characteristics of Relevant Big Data Types for Precision Medicine
  • Precision Medicine Data Sources-Current and Future Scenarios
  • Precision Medicine Vendor Landscape
  • Precision Medicine-Multiple Stakeholders
  • Precision Medicine Landscape-Drug and Diagnostic
  • Precision Medicine Landscape-Device and Technology
  • Precision Medicine Landscape-Provider and Payer
4. Precision Medicine Market Projections (2015–2025)
  • Scenario Contingent Projections for Core Precision Medicine Segment
  • Forecast Assumptions for Core Precision Medicine Segment
  • Core Precision Medicine Segment-Revenue Forecast Scenario Analysis
  • Core Precision Medicine Segment-Revenue Forecast by Sub Segments
  • Forecast Assumptions-Core Precision Medicine Key Sub Segments
  • Growth Opportunity by Major Market Segments
  • Personalized Medicines in the Late-stage Pipeline
  • Selected Population-Scale Genome Sequencing Projects Globally
  • United States-Major Regulatory Developments and Future Implications
  • Europe-Major Regulatory Developments and Future Implications
  • China-Major Regulatory Developments and Future Implications
  • South Korea-Major Regulatory Developments and Future Implications
  • APAC-Major Regulatory Developments and Future Implications
  • Others-Major Regulatory Developments and Future Implications
5. Opportunity Analysis-CDx Biomarkers and Targeted Therapeutics Segment
  • Integrating Companion Diagnostic (CDx) into Pharma Drug (Rx) Development Value Chain
  • Growth Opportunity 1-Companion Diagnostics Biomarkers and Targeted Therapeutics
  • Limitations in the Market Puts Us Far Away from the Reality of Precision Medicine
  • Precision Therapeutics’ Biomarkers and Available Test Counts (2016)
  • Top Areas of Companion Biomarker Research
  • Selected Countries-Companion Diagnostic (CDx) Attractiveness
  • Precision Medicine Drug (Rx) to Diagnostic (Dx) Journey
  • Pharma Rx / Dx Partnership Deals Continue to Rise
  • How Much Does it Take to Commercialize a Low-end CDx Test?
  • Current Pharma’s CDx Participant Strategies Discussion
  • Growth Opportunities in CDx Technology Providers
  • Role of CDx in Optimizing Clinical Trials-Developing Cancer Therapies
  • Evolving Patient-centric Clinical Trials Models for Precision Therapeutic
  • Insilico Medicine-Deep Learning Platform Solutions for Drug Repurposing and Biomarker Development
  • Companion Diagnostic Stakeholders and Their Expectations
6. Opportunity Analysis-Omics and Diagnostics Segment
  • Precision Medicine Patient Stratification by Omics / Diagnostic Factors
  • Growth Opportunity 2-Genomics Technologies for Precision Diagnostic
  • Evolution of Molecular Diagnostics (MDx) and Sequencing Technologies
  • Lifecycle Analysis-Genomics Technologies for Precision Diagnostic
  • Growth Opportunity Discussion-Genomics Technologies for Precision Diagnostic
  • Companion Diagnostics by Disease and Technology-PCR is Highly Prevalent in CDx
  • Opportunity Analysis-MDx Technologies in Precision Medicine Practice
  • Opportunity Analysis-Future of POCT in Precision Medicine Practice
  • Large IVD Players Expanding Product Portfolio to Include Liquid Biopsy
  • Liquid Biopsy will Become Mainstream Within 1-4 Years in the United States
  • NGS Provider and Pharma Important Collaborations
  • Genomic Data Analysis Pipeline and Phases
  • Growth Opportunity 3-NGS Informatics Solutions
  • Evolving Genomics-based Precision Diagnostic Business Model
  • Selected NGS Vendor Landscape
  • Genomics Data Workflow-From Sample to Clinical Reports
  • Iggbo-On-Demand Anytime / Anywhere Blood Draw Service
  • Business Model-Illumina’s End-to-End Genomics Solution
  • 23andMe Business Model
  • Selected Companies-DTC Business Model for Genome Data Services
  • Selected Companies to Watch
  • Selected Companies to Watch (continued)
  • Precision Medicine Patient Stratification by Molecular Imaging Diagnostic
  • Commonly Used Radiotracers in PET or SPECT Studies
  • Growth Opportunity 4-Molecular Imaging Diagnostics and Informatics Solutions
  • Visionary Scenario for Molecular Imaging Informatics in 2025
  • Molecular Imaging Diagnostic Solutions Vendor Landscape
  • Precision Medicine Patient Stratification by Biobanking Solutions
  • Growth Opportunity 5-Human Specimen and Imaging Biobanks
  • Biobanks Types and Role in Targeted Therapy Development
  • Biobanking Automation Tool Types and Selected Vendors
  • Human Specimen Biobank Global Penetration
7. Opportunity Analysis-Non-omics Patient Stratification Solutions
  • Precision Medicine Patient Stratification beyond Omics / Dx Factors
  • Major Non-Omic Patient Stratification Technologies into Precision Medicine Practice
  • Growth Opportunity 6-Remote Patient Monitoring Solution
  • Growth Opportunity 7-Exogenous Factors and Lifestyle Monitoring
  • Validic API-Cloud-based Asset Light SaaS Model
  • physiQ-Personalized Predictive Analytics Solution
  • Alternate Business Models-Innovation Beyond the Pill
  • Omada-Next-Generation Digital Behavioral Therapies
  • Zipongo Inc.-Digital Nutrition Company
  • Healint-Global Platform for Patient Monitoring, Research, and Clinical Data (Singapore)
  • MolecularMatch-Democratizing Cancer Clinical Trial Process
8. Opportunity Analysis-Clinical Decision Support System (CDSS) Bridging the Last Miles for Precision Medicine Practice
  • Healthcare Digital Transformation Setting the Stage Right for Precision Medicine Practice
  • Internet of Medical Things Enabling Patient Stratification and Lifestyle Tracking for Precision Medicine Practice
  • CDSS Bridging the Last Miles for Precision Medicine Integration into Clinical Practice
  • Growth Opportunity 8-Clinical Decision Support Systems
  • Current Barriers to CDSS Adoption into Clinical Practice
  • Business Model-N-of-One’s Molecular Decision Support for Precision Oncology
  • Case Study-NantHealth’s CLINICS Solutions
  • Company to Watch
9. Key Conclusions
  • Global Precision Health Overall Market Opportunity (2015–2025)
  • Strategic Imperatives for Pharma (Rx) and Diagnostic (Dx) Companies
  • Timeline for Precision Medicine Opportunity Realization
  • Quest’s Cancer Diagnostics Now Powered by IBM Watson Health
  • Partnering to Innovate-Beyond Conventional Boundaries
  • Intel’s 2020 Vision for Precision Medicine
  • Selected Open Source Vendors in Precision Medicine Ecosystem
  • Conclusions
  • Legal Disclaimer
10. Appendix
  • List of Acronyms and Explanations
  • Population Genome Sequencing Initiatives-International Level
  • Population Genome Sequencing Initiatives-National Level
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll